Article
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.
Science translational medicine - 3 Sept 2025
McAndrews Kathleen M, Paradiso Francesca, Stalnecker Clint A, Chellakkan Benson S, Thege Fredrik I, Peng David H, Moreno Diaz Barbara A, Sugimoto Hikaru, Patel Sarah I, Mahadevan Krishnan K, Kirtley Michelle L, Wills Danielle, Sockwell Amari M, Fonseca Andre Luis F, Liu Yunhe, Rajapakshe Kimal I, Yee Nathaniel G, Tran Phuong Thao, Omar Huda Alchikh, Tedeschi Antonio, Schischlik-Siegl Fiorella, Boghossian Andrew S, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Rudolph Dorothea, Aichinger Martin, Ebner Florian, Artemov Artem V, Lipp Jesse, Pisarsky Laura, Herrmann Valerie Laura, Park John, Rippmann Jörg F, Schaaf Otmar, Chandler Vanessa, Williams Mariah, Deckard Charles E, Wang Linghua, Der Channing J, Vellano Christopher, Guerrero Paola A, Heffernan Timothy P, Kalluri Raghu, Maitra Anirban
Abstract excerpt
KRAS is among the most frequently mutated oncogenes in cancer, and for decades, efforts at pharmacological blockade of its function in solid cancers have been unsuccessful. A notable advance in this endeavor is the recent development of small-molecule KRAS inhibitors, which enable direct targeting of the mutant oncoprotein. Here, we comprehensively evaluated the preclinical efficacy of BI-2493, a first-in-class...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.